An ancillary biomarker study of Gio-Tag Japan.

An ancillary biomarker study of Gio-Tag Japan. - An ancillary biomarker study of Gio-Tag Japan.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043299

Enrollment

Registered

2021-02-15

Start date

2020-10-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled in the main study (Gio-Tag Japan) (UMIN000037452)

Exclusion criteria

Exclusion criteria: Patients with no residual specimens collected in the main study (Gio-tag Japan) Patients whose data was rejected in the main study

Design outcomes

Primary

Measure	Time frame
Comparison of T790M rate before and after treatment with afatinib.	—

Secondary

Measure	Time frame
Correlation between T790M rate before treatment with afatinib and response rate, progression-free survival, and overall survival of afatinib. Correlation between the T790M rate before the treatment with afatinib and the transition rate to second-line treatment. Correlation between T790M rate before treatment with afatinib, and response rate and progression-free survival rate of second-line treatment.	—

Measure

Time frame

Correlation between T790M rate before treatment with afatinib and response rate, progression-free survival, and overall survival of afatinib. Correlation between the T790M rate before the treatment with afatinib and the transition rate to second-line treatment. Correlation between T790M rate before treatment with afatinib, and response rate and progression-free survival rate of second-line treatment.

—

Countries

Japan

Contacts

Public ContactTakashi Yokoi

Hyogo College of Medicine Hospital Respiratory Medicine

ta-yokoi@hyo-med.ac.jp0798-45-6597

Outcome results